IP Library Granted Patent US 10,723,769
Granted Patent B2
US 10,723,769 · App. 15/561,332 · Granted Jul 28, 2020

Immunoglobulin-binding protein and affinity carrier using same

Inventors: Jun-ichi Yasuoka (Minato-ku, JP); Takashi Ichii (Minato-ku, JP); Satoshi Nakamura (Minato-ku, JP); Tomonori Shiotani (Minato-ku, JP); Kaori Itaya (Minato-ku, JP)
Assignees: JSR CORPORATION; JSR LIFE SCIENCES CORPORATION
C07K14/195C07K1/22C07K14/31C07K16/1203C07K17/04C07K17/08C12N5/10C12N15/09G01N33/6854
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,723,769
App. No.
15/561,332
Granted
Jul 28, 2020
Kind
B2
Abstract

Provided is an affinity chromatography carrier that maintains high immunoglobulin-binding capacity and high alkali resistance. An immunoglobulin-binding protein including at least one modified immunoglobulin-binding domain, the modified immunoglobulin-binding domain being a polypeptide consisting of an amino acid sequence of an immunoglobulin-binding domain selected from the group consisting of the B domain, Z domain, C domain, and variants thereof of Staphylococcus aureus protein A, in which at least one amino acid residue is inserted between positions corresponding to the 3-position and position 4 of the amino acid sequence of the B domain, Z domain or C domain.

Claims (60)

1. An immunoglobulin-binding protein comprising at least one modified immunoglobulin-binding domain,

wherein the at least one modified immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 1, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 2, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 3, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

2. The immunoglobulin-binding protein according to claim 1 , wherein the immunoglobulin-binding domain consisting of an amino acid sequence having at least 85% identity with an amino acid sequence set forth in any one of SEQ ID NO: 1 to SEQ ID NO: 3 is a Val1/Ala29 variant.

3. The immunoglobulin-binding protein according to claim 1 , comprising 2 to 12 units of the modified immunoglobulin-binding domain.

4. An affinity carrier comprising the immunoglobulin-binding protein according to claim 1 immobilized on a base material insoluble in water.

5. A method for isolating an immunoglobulin, the method comprising contacting a solution comprising an immunoglobulin with the affinity carrier according to claim 4 .

6. A method for producing an antibody medicine, the method comprising contacting a solution comprising an immunoglobulin with the affinity carrier according to claim 4 .

7. The immunoglobulin-binding protein according to claim 1 , wherein the at least one modified immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 1, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 2, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, wherein at least one amino acid residue is inserted in said amino acid sequence between position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 3, wherein at least one amino acid residue is inserted in said amino acid sequence between positions corresponding to the position 3 and position 4 of the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

8. A method for producing an immunoglobulin-binding protein, the method comprising:

inserting, with regard to an amino acid sequence of an immunoglobulin-binding domain at least one amino acid residue between positions corresponding to the position 3 and position 4 of the amino acid sequence of the immunoglobulin-binding domain,

wherein the immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

9. The method according to claim 8 , wherein the immunoglobulin-binding domain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in any one of SEQ ID NO: 1 to SEQ ID NO: 3 is a Val1/Ala29 variant.

10. The method according to claim 8 , further comprising linking 2 to 12 units of the immunoglobulin-binding domain having at least one amino acid residue inserted therein.

11. The method according to claim 8 , wherein the immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

12. A method for increasing the immunoglobulin-binding capacity of an immunoglobulin-binding protein, the method comprising:

inserting, with regard to an amino acid sequence of an immunoglobulin-binding domain at least one amino acid residue between positions corresponding to the position 3 and position 4 of the amino acid sequence of the immunoglobulin-binding domain,

wherein the immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

13. The method according to claim 12 , wherein the immunoglobulin-binding domain is selected from the group consisting of:

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 1,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 2,

a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO: 3, and

a polypeptide consisting of an amino acid sequence having at least 90% identity with the amino acid sequence set forth in SEQ ID NO: 3, and

wherein the at least one amino acid residue to be inserted is at least one selected from the group consisting of Ala, Arg, Asp, Gln, Glu, His, Met, Thr, Val, Phe, Leu, Ile, Pro, Trp, and Tyr.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2026
From: MBL MATERIALS CO., LTD.
To: JSR CORPORATION
Reel/Frame 074227/0181 →
CHANGE OF NAME Recorded Mar 25, 2026
From: JSR LIFE SCIENCES CORPORATION
To: MBL MATERIALS CO., LTD.
Reel/Frame 075228/0228 →
CHANGE OF ADDRESS Recorded Mar 25, 2026
From: MBL MATERIALS CO., LTD.
To: MBL MATERIALS CO., LTD.
Reel/Frame 075228/0238 →
CHANGE OF NAME Recorded Sep 22, 2025
From: JICC-02 CORPORATION
To: JSR CORPORATION
Reel/Frame 072326/0282 →
MERGER Recorded Sep 22, 2025
From: JSR CORPORATION
To: JICC-02 CORPORATION
Reel/Frame 072935/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: YASUOKA, JUN-ICHI; ICHII, TAKASHI; NAKAMURA, SATOSHI; SHIOTANI, TOMONORI; ITAYA, KAORI
To: JSR CORPORATION; JSR LIFE SCIENCES CORPORATION
Reel/Frame 043683/0355 →
Priority Claims (1)
JP 2015-063519 · Mar 26, 2015 · national
Continuity (1)
Related Publication 20180105560A1 · Apr 19, 2018